Alnylam Pharmaceuticals’ (ALNY) Outperform Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note released on Wednesday,Benzinga reports. The firm currently has a $310.00 price target on the biopharmaceutical company’s stock.

ALNY has been the topic of a number of other research reports. Canaccord Genuity Group upped their target price on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. Sanford C. Bernstein cut their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Morgan Stanley increased their target price on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Scotiabank lowered their target price on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research note on Friday, February 14th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $296.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $304.26.

Alnylam Pharmaceuticals Stock Down 0.5 %

NASDAQ ALNY opened at $243.86 on Wednesday. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39. The firm has a market capitalization of $31.57 billion, a price-to-earnings ratio of -112.38 and a beta of 0.35. The company has a fifty day moving average of $254.33 and a two-hundred day moving average of $262.59.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,752 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $251.00, for a total value of $439,752.00. Following the completion of the sale, the chief marketing officer now directly owns 15,705 shares in the company, valued at $3,941,955. This trade represents a 10.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 72,986 shares of company stock worth $20,397,849. 1.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ALNY. GF Fund Management CO. LTD. acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $637,000. Focus Partners Advisor Solutions LLC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $203,000. Worldquant Millennium Advisors LLC grew its position in Alnylam Pharmaceuticals by 156.6% during the 4th quarter. Worldquant Millennium Advisors LLC now owns 150,191 shares of the biopharmaceutical company’s stock worth $35,341,000 after purchasing an additional 91,671 shares during the last quarter. Zurich Insurance Group Ltd FI acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $6,583,000. Finally, Vident Advisory LLC raised its holdings in shares of Alnylam Pharmaceuticals by 21.2% in the fourth quarter. Vident Advisory LLC now owns 1,327 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 232 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.